Key result
Left ventricular global longitudinal strain measured by feature-tracking CMRI was independently associated with all-cause mortality in patients with end-stage kidney disease (HR 1.08; 95% CI 1.01-1.16).
Why the study?
Patients with end-stage kidney disease are at increased risk of premature death from cardiovascular disease, and the prognostic value of LV global longitudinal strain by feature-tracking CMRI in this population was unclear.
Does left ventricular global longitudinal strain (LV-GLS) measured by feature-tracking CMRI predict all-cause mortality in patients with end-stage kidney disease?
Cohort (n=215)
No
Does left ventricular global longitudinal strain (LV-GLS) measured by feature-tracking CMRI predict all-cause mortality in patients with end-stage kidney disease?
Hazard Ratio: 1.08 (95% CI 1.01–1.16)
LV-GLS measured by feature-tracking CMRI is independently associated with all-cause mortality in ESKD patients, identifying risk even when LVEF is preserved.
LV-GLS may predict mortality in ESKD; leaves open its incremental value over standard measures in prospective cohorts.
BACKGROUND: Patients with end-stage kidney disease (ESKD) are at increased risk of premature death, with cardiovascular disease being the predominant cause of death. We hypothesized that left ventricular global longitudinal strain (LV-GLS) measured by feature-tracking cardiovascular magnetic resonance imaging (CMRI) would be associated with all-cause mortality in patients with ESKD. METHODS: A pooled analysis of CMRI studies in patients with ESKD acquired within a single centre between 2002 and 2016 was carried out. CMR parameters including LV ejection fraction (LVEF), LV mass index, left atrial emptying fraction (LAEF) and LV-GLS were measured. We tested independent associations of CMR parameters with survival using a multivariable Cox model. RESULTS: Among 215 patients (mean age 54 years, 62% male), mortality was 53% over a median follow-up of 5 years. The median LVEF was 64.7% [interquartile range (IQR) 58.5-70.0] and the median LV-GLS was -15.3% (IQR -17.24 to -13.6). While 90% of patients had preserved LVEF (>50%), 58% of this group had abnormal LV-GLS (>-16%). On multivariable Cox regression, age {hazard ratio [HR] 1.04 [95% confidence interval (CI) 1.02-1.05]}, future renal transplant [HR 0.29 (95% CI 0.17-0.47)], LAEF [HR 0.98 (95% CI 0.96-1.00)] and LV-GLS [HR 1.08 (95% CI 1.01-1.16)] were independently associated with mortality. CONCLUSIONS: In this cohort of patients with ESKD, LV-GLS on feature-tracking CMRI and LAEF was associated with all-cause mortality, independent of baseline clinical variables and future renal transplantation. This effect was present even when >90% of the cohort had normal LVEF. Using LV-GLS instead of LVEF to diagnose cardiac dysfunction in patients with ESKD could result in a major advance in our understanding of cardiovascular disease in ESKD.
No takes yet. Share an insight, caveat, or question.
Rankin et al. (2021) conducted a cohort in End-stage kidney disease (n=215). Left ventricular global longitudinal strain (LV-GLS) was evaluated on All-cause mortality (HR 1.08, 95% CI 1.01-1.16). Left ventricular global longitudinal strain measured by feature-tracking CMRI was independently associated with all-cause mortality in patients with end-stage kidney disease (HR 1.08; 95% CI 1.01-1.16).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: